Galderma Pharmaceutical Expands in Quebec
Location Canada 2010
Galderma, which produces the skin care line Cetaphil, received more than $38 million from Investissement Quebec, the province's investment program, which targets product development projects by Quebec companies. The sum includes a non-refundable $3.8 million financial contribution that will help Galderma modernize and expand its drug manufacturing plant in Bai-d'Urfe.
"The government's support was a decisive factor in Galderma's decision to locate its center of excellence in Quebec," says Michel Sauvageau, manager of the Bai-d'Urfe plant. "In response to the progress of emerging countries in biopharmaceuticals, this investment in our manufacturing facility will increase its capacity and make it truly state-of-the-art."
The funds will also allow Galderma to consolidate 240 positions and create 30 new, specialized jobs.
Amazon Canada Plans Fulfillment Centre in Hamilton & Delivery Station in Stoney Creek, Ontario
CNTNR Expands Operations in Welland, Ontario
Merit Functional Foods Receives Financing for Plant Protein Production in Winnipeg, Manitoba
How are Uncertain Times Altering Company Location Strategies?
Infrastructure Investment as an Economic Stimulus Tool
34th Annual Corporate Survey & the 16th Annual Consultants Survey
Site Selection 2020: The Importance of “Regional Depth” with Global Reach
2020 Gold & Silver Shovel Awards Recognize State and Local Economic Development Efforts
Shifts in Mobility and Transportation Infrastructure in a COVID-19 World
2020 Auto/Aero Site Guide